SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma
NCT01329289
Withdrawn
The purpose of this study is to determine if adding SOM230 LAR to bortezomib and dexamethasone is better than bortezomib and dexamethasone alone and if it should be investigated further.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2016
Locations: Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Multiple Myeloma in Relapse, Multiple Myeloma
Register for Updates
Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy
NCT01500213
Completed
This is a Phase 3, multicenter, randomized, parallel-group, double-blind, active-controlled study of rolapitant in subjects receiving HEC. Rolapitant or placebo will be administered 1-2 hours prior to initiation of chemotherapy on Day 1 with granisetron and dexamethasone. Subjects will record all events of emesis and use of rescue medication for established nausea and/or vomiting, and will indicate the severity of nausea they experienced in each of the previous 24 hours in the Nausea and Vomitin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/02/2016
Locations: TESARO Inc, Waltham, Massachusetts
Conditions: Chemotherapy-induced Nausea and Vomiting
Register for Updates
Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy
NCT01500226
Completed
This is a Phase 3, multicenter, randomized, parallel-group, double-blind, active-controlled study of rolapitant in subjects receiving MEC. Rolapitant or placebo will be administered prior to the initiation of chemotherapy on Day 1 with granisetron and dexamethasone. Subjects will record all events of emesis and the use of rescue medication for established nausea and/or vomiting, and will indicate the severity of nausea they experienced in each of the previous 24 hours in the Nausea and Vomiting... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/02/2016
Locations: TESARO Inc, Waltham, Massachusetts
Conditions: Chemotherapy-induced Nausea and Vomiting
Register for Updates
Calcitriol and Dexamethasone in Patients With Myelodysplastic Syndromes
NCT00030069
Completed
This is a study to determine the response rate in patients with myelodysplastic syndromes treated with calcitriol and dexamethasone.
Gender:
ALL
Ages:
All
Trial Updated:
01/14/2016
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Myelodysplastic Syndromes
Register for Updates
Single Oral Dose of Dexamethasone Versus Five Days of Prednisone in Adult Asthma
NCT01241006
Completed
This study seeks to compare the effectiveness of a single dose of oral dexamethasone versus 5 days of oral prednisone in the treatment of mild to moderate asthma exacerbations to prevent relapse with an unscheduled return visit to a health care provider for additional asthma treatment within 14 days. The investigators hypothesize that the two treatments will be equally effective in relapse prevention.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/05/2016
Locations: Alameda County Medical Center, Oakland, California
Conditions: Asthma, Reactive Airway Disease
Register for Updates
Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma
NCT00458705
Completed
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or stopping them from dividing. Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Giving bortezomib together with doxorubicin hydrochloride liposome and dexamethasone follow... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/16/2015
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion
NCT01827722
Unknown
CRVO occurs when the vessels in the back of the eye become blocked. This creates a dangerous condition because the vessels are weak and prone to leakage. This results in the development of macular edema. Previous studies have shown that inflammatory mediators and growth factors, such as vascular endothelial growth factor (VEGF), are elevated in patients with macular edema associated with CRVO. Ozurdex® is approved by the Food and Drug Administration (FDA) and is available by prescription for m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2015
Locations: Retina Vitreous Associates Medical Group, Beverly Hills, California +4 locations
Conditions: Macular Edema, Central Retinal Vein Occlusion
Register for Updates
Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
NCT00693433
Completed
This phase I trial is studying the side effects and best dose of temsirolimus when given together with dexamethasone in treating patients with recurrent or refractory multiple myeloma. Temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving temsirolimus together with dex... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2015
Locations: Veteran's Administration Medical Center, Las Angeles, California
Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Register for Updates
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
NCT01421173
Completed
The goal of this clinical research study is to find the highest tolerable dose of vorinostat that can be given with gemcitabine, busulfan, and melphalan with a stem cell transplant. Researchers also want to learn about the safety and level of effectiveness of this combination. Busulfan and melphalan are designed to kill cancer cells by binding to DNA (the genetic material of cells), which may cause cancer cells to die. Gemcitabine is designed to disrupt the growth of cancer cells, which may ca... Read More
Gender:
ALL
Ages:
Between 12 years and 65 years
Trial Updated:
11/17/2015
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
NCT00402766
Completed
Primary Objective: * To determine the maximum tolerated dose of the combination of cisplatin, imatinib mesylate, and pemetrexed in metastatic malignant mesothelioma. Secondary Objectives: * To explore the biologic effects of cisplatin, imatinib mesylate, and pemetrexed on tumor tissue by: * histologic analysis of biopsy tissue * by non-invasive assessments of tumor vascularity performed before, during and after treatment * electron microscopy analysis of endothelial cell architecture after pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/16/2015
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Mesothelioma
Register for Updates
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema
NCT02036424
Completed
To determine if there is visual benefit with Ozurdex treatment every three months compared to monthly anti-VEGF alone, in subjects with persistent diabetic macular edema. The investigator hypothesizes more frequent administration of Ozurdex in patients that have persistent diabetic macular edema will result in a more rapid and sustained improvement of visual acuity and/or optical coherence topography (OCT) compared to the use of anti-VEGF alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2015
Locations: Raj K Maturi MD PC, Indianapolis, Indiana
Conditions: Diabetic Macular Edema
Register for Updates
Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies
NCT01009931
Terminated
This phase II trial is studying the side effects and how well giving tetradecanoylphorbol acetate together with dexamethasone and choline magnesium trisalicylate works in treating patients with relapsed or refractory acute myeloid leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/02/2015
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Leukemia
Register for Updates